BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement with CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093). The agreement secures BeiGene the global development, manufacturing, and commercialization rights to CSPC’s methionine adenosyltransferase 2A (MAT2A) inhibitor, SYH2039.
Financial Details and Milestones of the Agreement
As per the terms of the deal, CSPC is to receive an upfront payment of USD 150 million from BeiGene. Furthermore, CSPC is eligible for additional payments of up to USD 135 million in development milestones and a substantial USD 1.55 billion in sales milestones, complemented by tiered annual net sales commission. This agreement not only highlights the potential of SYH2039 but also signifies a significant collaboration between two leading pharmaceutical companies.
SYH2039: A Promising AI-Driven Clinical Drug Candidate
SYH2039, developed from CSPC’s AI-driven small molecule design platform, has shown promising results in pre-clinical studies. It has been effective in inhibiting the growth of multiple MTAP deficient tumor cells, including non-small cell lung cancer, glioma, gastroesophageal cancer, pancreatic cancer, and bladder cancer. The drug candidate has demonstrated excellent in vitro and in vivo activity, along with favorable pharmacokinetic (PK) characteristics and safety. SYH2039 is currently undergoing a Phase I clinical study in China, either as a monotherapy or in combination with a PRMT5 inhibitor and other drugs. Preliminary results from these studies have indicated good safety, PK behavior, and PK-PD correlation.-Fineline Info & Tech
